{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:39:55Z","timestamp":1788309595655,"version":"build-2803163510"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40263-026-01311-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:09:41Z","timestamp":1782216581000},"page":"1051-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD"],"prefix":"10.1007","volume":"40","author":[{"given":"Monica","family":"Margoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"2","key":"1311_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","volume":"20","author":"G Fadda","year":"2021","unstructured":"Fadda G, Armangue T, Hacohen Y, Chitnis T, Banwell B. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurol. 2021;20(2):136\u201349.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1311_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/jnnp-2024-335175","volume":"96","author":"G Gombolay","year":"2025","unstructured":"Gombolay G, Johnson L, King R, Hebert M, Banwell B, Chitnis T, et al. Worldwide epidemiology of paediatric multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition. J Neurol Neurosurg Psychiatry. 2025;96(8):814\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1311_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fped.2020.00339","volume":"8","author":"S Tenembaum","year":"2020","unstructured":"Tenembaum S, Yeh EA, Guthy-Jackson Foundation International Clinical C. Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis. Front Pediatr. 2020;8:339.","journal-title":"Front Pediatr"},{"key":"1311_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, et al. E.U. paediatric MOG consortium consensus: part 1\u2014classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:2\u201313.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"1311_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200065","volume":"10","author":"M Nosadini","year":"2023","unstructured":"Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Pratico AD, et al. Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200065.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"1311_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","volume":"19","author":"T Armangue","year":"2020","unstructured":"Armangue T, Olive-Cirera G, Martinez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Munoz-Batista M, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19(3):234\u201346.","journal-title":"Lancet Neurol"},{"key":"1311_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105921","volume":"120","author":"M Filippi","year":"2025","unstructured":"Filippi M, Margoni M, Banwell B, Chitnis T, Dale R, Fadda G, et al. Smouldering disease in paediatric-onset multiple sclerosis. EBioMedicine. 2025;120:105921.","journal-title":"EBioMedicine"},{"issue":"4","key":"1311_CR8","first-page":"265","volume":"20","author":"B Kolb","year":"2011","unstructured":"Kolb B, Gibb R. Brain plasticity and behaviour in the developing brain. J Can Acad Child Adolesc Psychiatry. 2011;20(4):265\u201376.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"3","key":"1311_CR9","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","volume":"269","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269(3):1316\u201334.","journal-title":"J Neurol"},{"key":"1311_CR10","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X392955250815095236","author":"M Margoni","year":"2025","unstructured":"Margoni M, Battistini L, Centonze D, Furlan R, Gasperini C, Filippi M. Pharmacodynamics and pharmacokinetics of ublituximab compared with other anti-Cd20 monoclonal antibodies for multiple sclerosis treatment. Curr Neuropharmacol. 2025. https:\/\/doi.org\/10.2174\/011570159X392955250815095236.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"1311_CR11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s13311-022-01252-5","volume":"19","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA. Does ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers. Neurotherapeutics. 2022;19(4):1216\u201328.","journal-title":"Neurotherapeutics"},{"key":"1311_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","volume":"19","author":"RR Hardy","year":"2001","unstructured":"Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595\u2013621.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"1311_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nri3570","volume":"14","author":"MR Clark","year":"2014","unstructured":"Clark MR, Mandal M, Ochiai K, Singh H. Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol. 2014;14(2):69\u201380.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1311_CR14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jaci.2022.06.006","volume":"150","author":"F Borriello","year":"2022","unstructured":"Borriello F, Pasquarelli N, Law L, Rand K, Raposo C, Wei W, et al. Normal B-cell ranges in infants: a systematic review and meta-analysis. J Allergy Clin Immunol. 2022;150(5):1216\u201324.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1311_CR15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506.","journal-title":"Haematologica"},{"key":"1311_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.0105-2896.2004.0109.x","volume":"197","author":"R Carsetti","year":"2004","unstructured":"Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197:179\u201391.","journal-title":"Immunol Rev"},{"issue":"11","key":"1311_CR17","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1182\/blood-2004-11-4284","volume":"105","author":"GP Sims","year":"2005","unstructured":"Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105(11):4390\u20138.","journal-title":"Blood"},{"issue":"3","key":"1311_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2009-07-234799","volume":"115","author":"S Suryani","year":"2010","unstructured":"Suryani S, Fulcher DA, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood. 2010;115(3):519\u201329.","journal-title":"Blood"},{"issue":"2","key":"1311_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cyto.a.24507","volume":"101","author":"R Carsetti","year":"2022","unstructured":"Carsetti R, Terreri S, Conti MG, Fernandez Salinas A, Corrente F, Capponi C, et al. Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions. Cytom A. 2022;101(2):131\u20139.","journal-title":"Cytom A"},{"issue":"7502","key":"1311_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature13300","volume":"509","author":"AD Gitlin","year":"2014","unstructured":"Gitlin AD, Shulman Z, Nussenzweig MC. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature. 2014;509(7502):637\u201340.","journal-title":"Nature"},{"issue":"12","key":"1311_CR21","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1084\/jem.20091087","volume":"206","author":"M Seifert","year":"2009","unstructured":"Seifert M, Kuppers R. Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation. J Exp Med. 2009;206(12):2659\u201369.","journal-title":"J Exp Med"},{"issue":"8","key":"1311_CR22","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/eji.200939531","volume":"39","author":"SG Tangye","year":"2009","unstructured":"Tangye SG, Tarlinton DM. Memory B cells: effectors of long-lived immune responses. Eur J Immunol. 2009;39(8):2065\u201375.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1311_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/eji.202149216","volume":"52","author":"C Delaloy","year":"2022","unstructured":"Delaloy C, Schuh W, Jack HM, Bonaud A, Espeli M. Single-cell resolution of plasma cell fate programming in health and disease. Eur J Immunol. 2022;52(1):10\u201323.","journal-title":"Eur J Immunol"},{"issue":"6","key":"1311_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250116","volume":"53","author":"J Dirks","year":"2023","unstructured":"Dirks J, Viemann D, Beyersdorf N, Hartel C, Morbach H. Insights into B-cell ontogeny inferred from human immunology. Eur J Immunol. 2023;53(6):e2250116.","journal-title":"Eur J Immunol"},{"issue":"4","key":"1311_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7555\/JBR.29.20150035","volume":"29","author":"M Bemark","year":"2015","unstructured":"Bemark M. Translating transitions\u2014how to decipher peripheral human B cell development. J Biomed Res. 2015;29(4):264\u201384.","journal-title":"J Biomed Res"},{"issue":"7","key":"1311_CR26","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.4049\/jimmunol.0803391","volume":"182","author":"J Lee","year":"2009","unstructured":"Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE. Identification and characterization of a human CD5+ pre-naive B cell population. J Immunol. 2009;182(7):4116\u201326.","journal-title":"J Immunol"},{"issue":"2","key":"1311_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","volume":"162","author":"H Morbach","year":"2010","unstructured":"Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol. 2010;162(2):271\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1311_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cyto.a.22520","volume":"87","author":"F Tosato","year":"2015","unstructured":"Tosato F, Bucciol G, Pantano G, Putti MC, Sanzari MC, Basso G, et al. Lymphocytes subsets reference values in childhood. Cytom A. 2015;87(1):81\u20135.","journal-title":"Cytom A"},{"issue":"1","key":"1311_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2350\/10-01-0785-OA.1","volume":"14","author":"ET Luning Prak","year":"2011","unstructured":"Luning Prak ET, Ross J, Sutter J, Sullivan KE. Age-related trends in pediatric B-cell subsets. Pediatr Dev Pathol. 2011;14(1):45\u201352.","journal-title":"Pediatr Dev Pathol"},{"issue":"1","key":"1311_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10875-025-01959-y","volume":"45","author":"E Aarimaa","year":"2025","unstructured":"Aarimaa E, Kesalainen A, Askeli S, Toivonen A, Savonius O, Bruck O, et al. Evaluating pediatric reference ranges for extended immunophenotyping from a finnish cohort against published references. J Clin Immunol. 2025;45(1):162.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1311_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/iid3.26","volume":"2","author":"M Duchamp","year":"2014","unstructured":"Duchamp M, Sterlin D, Diabate A, Uring-Lambert B, Guerin-El Khourouj V, Le Mauff B, et al. B-cell subpopulations in children: national reference values. Immun Inflamm Dis. 2014;2(3):131\u201340.","journal-title":"Immun Inflamm Dis."},{"issue":"6","key":"1311_CR32","doi-asserted-by":"publisher","first-page":"2208 e16","DOI":"10.1016\/j.jaci.2018.02.017","volume":"141","author":"E Blanco","year":"2018","unstructured":"Blanco E, Perez-Andres M, Arriba-Mendez S, Contreras-Sanfeliciano T, Criado I, Pelak O, et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J Allergy Clin Immunol. 2018;141(6):2208 e16-2219.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1311_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/cei.12149","volume":"174","author":"S Agrawal","year":"2013","unstructured":"Agrawal S, Smith SA, Tangye SG, Sewell WA. Transitional B cell subsets in human bone marrow. Clin Exp Immunol. 2013;174(1):53\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"1311_CR34","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1567-5769(01)00044-3","volume":"1","author":"D Verthelyi","year":"2001","unstructured":"Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol. 2001;1(6):983\u201393.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"1311_CR35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626\u201338.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"1311_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1191\/0961203304lu1094oa","volume":"13","author":"M Cutolo","year":"2004","unstructured":"Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13(9):635\u20138.","journal-title":"Lupus"},{"issue":"3","key":"1311_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2353\/ajpath.2008.071008","volume":"173","author":"D Fairweather","year":"2008","unstructured":"Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600\u20139.","journal-title":"Am J Pathol"},{"key":"1311_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690534","volume":"12","author":"M Ciocca","year":"2021","unstructured":"Ciocca M, Zaffina S, Fernandez Salinas A, Bocci C, Palomba P, Conti MG, et al. Evolution of human memory B cells from childhood to old age. Front Immunol. 2021;12:690534.","journal-title":"Front Immunol"},{"issue":"9","key":"1311_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","volume":"35","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, O\u2019Brien SM, Sweeney ML, Fox EJ, Cohen JA. Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs. 2021;35(9):985\u201397.","journal-title":"CNS Drugs"},{"key":"1311_CR40","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de Seze","year":"2023","unstructured":"de Seze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023;14:1004795.","journal-title":"Front Immunol"},{"issue":"6","key":"1311_CR41","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bjh.15132","volume":"180","author":"S Meyer","year":"2018","unstructured":"Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, et al. New insights in type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Br J Haematol. 2018;180(6):808\u201320.","journal-title":"Br J Haematol"},{"issue":"12","key":"1311_CR42","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1177\/1352458520932798","volume":"27","author":"A Ghezzi","year":"2021","unstructured":"Ghezzi A, Banwell B, Bar-Or A, Chitnis T, Dale RC, Gorman M, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: practical considerations. Mult Scler. 2021;27(12):1814\u201322.","journal-title":"Mult Scler"},{"issue":"1","key":"1311_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2014.02.007","volume":"51","author":"SJ Beres","year":"2014","unstructured":"Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014;51(1):114\u20138.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"1311_CR44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00415-015-7979-x","volume":"263","author":"J Salzer","year":"2016","unstructured":"Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016;263(2):322\u20136.","journal-title":"J Neurol"},{"issue":"2","key":"1311_CR45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/13524585231223069","volume":"30","author":"M Venet","year":"2024","unstructured":"Venet M, Lepine A, Maarouf A, Biotti D, Boutiere C, Casez O, et al. Control of disease activity with large extended-interval dosing of rituximab\/ocrelizumab in highly active pediatric multiple sclerosis. Mult Scler. 2024;30(2):261\u20135.","journal-title":"Mult Scler"},{"issue":"1","key":"1311_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25737","volume":"88","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol. 2020;88(1):42\u201355.","journal-title":"Ann Neurol"},{"issue":"5","key":"1311_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16228","volume":"31","author":"M Breu","year":"2024","unstructured":"Breu M, Sandesjo F, Milos RI, Svoboda J, Salzer J, Schneider L, et al. Rituximab treatment in pediatric-onset multiple sclerosis. Eur J Neurol. 2024;31(5):e16228.","journal-title":"Eur J Neurol"},{"key":"1311_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pediatrneurol.2023.04.020","volume":"145","author":"N Malani Shukla","year":"2023","unstructured":"Malani Shukla N, Casper TC, Ness J, Wheeler Y, Chitnis T, Lotze T, et al. Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments. Pediatr Neurol. 2023;145:125\u201331.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"1311_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1469-8749.2008.03246.x","volume":"51","author":"M Karenfort","year":"2009","unstructured":"Karenfort M, Kieseier BC, Tibussek D, Assmann B, Schaper J, Mayatepek E. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol. 2009;51(2):159\u201361.","journal-title":"Dev Med Child Neurol"},{"key":"1311_CR50","doi-asserted-by":"publisher","first-page":"1359938","DOI":"10.3389\/fneur.2024.1359938","volume":"15","author":"U Arkar","year":"2024","unstructured":"Arkar U, Vipotnik Vesnaver T, Osredkar D, Perkovic Benedik M, Bizjak N. Multiple sclerosis in a 4-year-old boy: a case report and literature review. Front Neurol. 2024;15:1359938.","journal-title":"Front Neurol"},{"key":"1311_CR51","first-page":"8731613","volume":"2019","author":"G Vartzelis","year":"2019","unstructured":"Vartzelis G, Maritsi D, Nikolaidou M, Garoufi A, Kilidireas C. Rituximab as rescue therapy for aggressive pediatric multiple sclerosis. Case Rep Pediatr. 2019;2019:8731613.","journal-title":"Case Rep Pediatr."},{"issue":"4","key":"1311_CR52","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000046","volume":"1","author":"G Longoni","year":"2014","unstructured":"Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e46.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"1311_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000188","volume":"3","author":"M Nosadini","year":"2016","unstructured":"Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e188.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"1311_CR54","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000201625","volume":"100","author":"R Pizzolato Umeton","year":"2023","unstructured":"Pizzolato Umeton R, Waltz M, Aaen GS, Benson L, Gorman M, Goyal M, et al. Therapeutic response in pediatric neuromyelitis optica spectrum disorder. Neurology. 2023;100(9):e985\u201394.","journal-title":"Neurology"},{"issue":"3","key":"1311_CR55","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dmcn.14336","volume":"62","author":"F Albassam","year":"2020","unstructured":"Albassam F, Longoni G, Yea C, Wilbur C, Grover SA, Yeh EA. Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease. Dev Med Child Neurol. 2020;62(3):390\u20135.","journal-title":"Dev Med Child Neurol"},{"key":"1311_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejpn.2025.10.002","volume":"59","author":"EM Wendel","year":"2025","unstructured":"Wendel EM, Chen JJ, Bertolini A, Blaschek A, Brilot F, Dale RC, et al. Treatment response in children with relapsing MOG-antibody associated disease. Eur J Paediatr Neurol. 2025;59:45\u201351.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"1311_CR57","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018;75(4):478\u201387.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1311_CR58","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200504","volume":"15","author":"R Suntornlohanakul","year":"2025","unstructured":"Suntornlohanakul R, Yea C, Yeh EA. Exploring treatment approaches in pediatric MOG antibody-associated disease: a survey of neurologists. Neurol Clin Pract. 2025;15(4):e200504.","journal-title":"Neurol Clin Pract."},{"issue":"1","key":"1311_CR59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","volume":"94","author":"G Spagni","year":"2023","unstructured":"Spagni G, Sun B, Monte G, Sechi E, Iorio R, Evoli A, et al. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94(1):62\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1311_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106675","volume":"103","author":"A Altelly","year":"2025","unstructured":"Altelly A, Mahmoud A, Mifsud V, Benedetti B, Lee G, Elhabet S, et al. Efficacy and safety of ocrelizumab in pediatric multiple sclerosis. Mult Scler Relat Disord. 2025;103:106675.","journal-title":"Mult Scler Relat Disord."},{"key":"1311_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106539","volume":"100","author":"R Alroughani","year":"2025","unstructured":"Alroughani R, AlMojel M, Al-Hashel J, Ahmed SF. Ocrelizumab for pediatric relapsing multiple sclerosis. Mult Scler Relat Disord. 2025;100:106539.","journal-title":"Mult Scler Relat Disord."},{"key":"1311_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2023.01.011","volume":"43","author":"C Bibinoglu Amirov","year":"2023","unstructured":"Bibinoglu Amirov C, Saltik S, Yalcinkaya C, Tutuncu M, Saip S, Siva A, et al. Ocrelizumab in pediatric multiple sclerosis. Eur J Paediatr Neurol. 2023;43:1\u20135.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"1311_CR63","first-page":"51","volume":"31","author":"R Nistri","year":"2025","unstructured":"Nistri R, De Meo E, Biswas A, Mankad K, Hemingway C, Ciccarelli O, et al. Anti-CD20 treatment in pre-pubertal onset paediatric MS patients. Mult Scler J. 2025;31(3):51.","journal-title":"Mult Scler J"},{"issue":"3","key":"1311_CR64","first-page":"1337","volume":"31","author":"B Banwell","year":"2025","unstructured":"Banwell B, Kotulska-Jozwiak K, Rost\u00e1sy K, Deiva K, Sato H, Filippi M, et al. Efficacy and safety of ocrelizumab compared with fingolimod in paediatric relapsing-remitting MS: results of the Phase III OPERETTA 2 study. Mult Scler J. 2025;31(3):1337\u20138.","journal-title":"Mult Scler J"},{"key":"1311_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105647","volume":"87","author":"Z Nasr","year":"2024","unstructured":"Nasr Z, Casper TC, Waltz M, Virupakshaiah A, Lotze T, Shukla N, et al. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024;87:105647.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"1311_CR66","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.78086","volume":"99","author":"AW Abrams","year":"2026","unstructured":"Abrams AW, Waltz M, Casper TC, Aaen G, Benson LA, Bernfeld EM, et al. Real-world effectiveness of switching to oral or infusion versus injectable disease-modifying therapy in pediatric multiple sclerosis. Ann Neurol. 2026;99(3):715\u201329.","journal-title":"Ann Neurol"},{"key":"1311_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pediatrneurol.2024.12.015","volume":"164","author":"B Spirek","year":"2025","unstructured":"Spirek B, Brenton JN. Safety and efficacy of fingolimod and ocrelizumab in pediatric patients with multiple sclerosis. Pediatr Neurol. 2025;164:89\u201396.","journal-title":"Pediatr Neurol"},{"issue":"11","key":"1311_CR68","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2025.2619","volume":"82","author":"V Pozzilli","year":"2025","unstructured":"Pozzilli V, Prados Carrasco F, Kim N, Abdel-Mannan O, Nistri R, Goebl P, et al. Slowly expanding lesions in pediatric-onset multiple sclerosis. JAMA Neurol. 2025;82(11):1197\u20139.","journal-title":"JAMA Neurol"},{"key":"1311_CR69","doi-asserted-by":"publisher","first-page":"175628642513811","DOI":"10.1177\/17562864251381173","volume":"18","author":"W Wu","year":"2025","unstructured":"Wu W, Ran Y, Hou C, Zhu H, Wu W, Chen WX, et al. Ofatumumab in pediatric multiple sclerosis: a case series. Ther Adv Neurol Disord. 2025;18:17562864251381172.","journal-title":"Ther Adv Neurol Disord"},{"issue":"13","key":"1311_CR70","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1177\/13524585251331855","volume":"31","author":"P Siriratnam","year":"2025","unstructured":"Siriratnam P, Gosling S, Bhojak M, Griffiths M, Kneen R, Wassmer E, et al. A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD. Mult Scler. 2025;31(13):1604\u20137.","journal-title":"Mult Scler"},{"issue":"1","key":"1311_CR71","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","volume":"17","author":"AM Khojah","year":"2019","unstructured":"Khojah AM, Miller ML, Klein-Gitelman MS, Curran ML, Hans V, Pachman LM, et al. Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol Online J. 2019;17(1):61.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"1311_CR72","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200430","volume":"12","author":"G Waldrop","year":"2025","unstructured":"Waldrop G, Sisodia N, Poole S, Pleasure S, Wilson MR, Guo CY, et al. Neutropenia associated with B cell-depleting therapies in multiple sclerosis and neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200430.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"2","key":"1311_CR73","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/13524585241303480","volume":"31","author":"V Viti","year":"2025","unstructured":"Viti V, Zanetta C, Rocca MA, Filippi M. Immune-mediated colitis: a class effect with anti-CD2O agents used to treat MS? Mult Scler. 2025;31(2):245\u20136.","journal-title":"Mult Scler"},{"issue":"10","key":"1311_CR74","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/13524585231195854","volume":"29","author":"T Kim","year":"2023","unstructured":"Kim T, Brinker A, Croteau D, Lee PR, Baldassari LE, Stevens J, et al. Immune-mediated colitis associated with ocrelizumab: a new safety risk. Mult Scler. 2023;29(10):1275\u201381.","journal-title":"Mult Scler"},{"key":"1311_CR75","doi-asserted-by":"publisher","unstructured":"Marefi A, Grasso EA, Garber L, Narula S, Waldman A, Bar-Or A, et al. Factors influencing early and late B-cell repopulation after Rituximab therapy in pediatric CNS inflammatory disorders. . Available at SSRN: https:\/\/ssrn.com\/abstract=5787568 or https:\/\/doi.org\/10.2139\/ssrn5787568.","DOI":"10.2139\/ssrn5787568"},{"issue":"2","key":"1311_CR76","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40120-018-0101-4","volume":"7","author":"C Lebrun","year":"2018","unstructured":"Lebrun C, Cohen M, Rosenthal-Allieri MA, Bresch S, Benzaken S, Marignier R, et al. Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders. Neurol Ther. 2018;7(2):373\u201383.","journal-title":"Neurol Ther."},{"issue":"3","key":"1311_CR77","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/1352458520952310","volume":"27","author":"A Riva","year":"2021","unstructured":"Riva A, Barcella V, Benatti SV, Capobianco M, Capra R, Cinque P, et al. Vaccinations in patients with multiple sclerosis: a Delphi consensus statement. Mult Scler. 2021;27(3):347\u201359.","journal-title":"Mult Scler"},{"issue":"4","key":"1311_CR78","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"6578","key":"1311_CR79","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296\u2013301.","journal-title":"Science"},{"issue":"4","key":"1311_CR80","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ana.26890","volume":"95","author":"G Fadda","year":"2024","unstructured":"Fadda G, Yea C, O\u2019Mahony J, Waters P, Yeh EA, Marrie RA, et al. Epstein\u2013Barr virus strongly associates with pediatric multiple sclerosis, but not myelin oligodendrocyte glycoprotein-antibody-associated disease. Ann Neurol. 2024;95(4):700\u20135.","journal-title":"Ann Neurol"},{"issue":"22","key":"1311_CR81","doi-asserted-by":"publisher","first-page":"12330","DOI":"10.1128\/JVI.01699-12","volume":"86","author":"SI Tracy","year":"2012","unstructured":"Tracy SI, Kakalacheva K, Lunemann JD, Luzuriaga K, Middeldorp J, Thorley-Lawson DA. Persistence of Epstein\u2013Barr virus in self-reactive memory B cells. J Virol. 2012;86(22):12330\u201340.","journal-title":"J Virol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01311-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01311-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01311-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:02:21Z","timestamp":1783659741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01311-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1311"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01311-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MM, PP, MF, MAR contributed to methodology, conceptualization, visualisation, writing\u2014original draft, and writing\u2014review and editing. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"MM reports grants and personal fees from Sanofi Genzyme, Merck Serono, Roche, Biogen, Amgen and Novartis. PP received speaker honoraria from Roche, Biogen, Novartis, Merck, Bristol Myers Squibb, Genzyme, Horizon and Sanofi, he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. MAR received consulting fees from Biogen, Bristol Myers Squibb, Roche; and speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Celgene, Horizon Therapeutics Italy, Merck Serono SpA, Mitsubishi-Tanabe Pharma, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for\n                      Multiple Sclerosis and Related Disorders\n                      ; and Associate Co-Editor for Europe and Africa for\n                      Multiple Sclerosis Journal\n                      . MF is Editor-in-Chief of the\n                      Journal of Neurology\n                      , Associate Editor of\n                      Human Brain Mapping\n                      ,\n                      Neurological Sciences,\n                      and\n                      Radiology\n                      ; received compensation for consulting services from Almirall, Biogen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Roche, Sanofi; speaking activities from Amgen, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Chiesi Italia SpA, Eisai, Eli Lilly, Fujirebio, Genzyme, Janssen, Merck, Neopharmed Gentili, Neuraxpharm, Novartis, Novo Nordisk, Roche, Sanofi, Takeda; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Eli Lilly, GE Healthcare Ltd, Merck, Neuraxpharm, Novartis, Roche, Sandoz, Sanofi, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}